<DOC>
	<DOC>NCT00754325</DOC>
	<brief_summary>The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.</brief_summary>
	<brief_title>Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb (BMS) clinical trial participation, please visit www.BMSStudyConnect.com. Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC) Measureable or evaluableonly disease human epidermal growth factor receptor 2+ (HER2+) or HER2 breast cancer Males and females â‰¥18 years of age Females are post menopausal or surgically sterile Recurrent or progressive advanced breast cancer (locallyadvanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant Aromatase Inhibitor (AI) treatment OR (b) during AI treatment in advanced setting (metastatic therapy) Pregnant or breast feeding &gt;1 chemotherapy regimen for advanced disease Pleural or pericardial effusion Serious cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>